{"id":"NCT02251990","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination in Treatment-Naïve Hepatitis C Virus Participants (MK-5172-067)","officialTitle":"A Phase III Randomized Multinational Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Treatment-Naïve Subjects With Chronic HCV GT 1, GT 4 and GT 6 Infection","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-01-28","primaryCompletion":"2016-09-27","completion":"2017-04-10","firstPosted":"2014-09-29","resultsPosted":"2017-10-17","lastUpdate":"2019-01-30"},"enrollment":489,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis C"],"interventions":[{"type":"DRUG","name":"Grazoprevir/Elbasvir","otherNames":["MK-5172A"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Immediate Treatment Group (ITG): Grazoprevir/Elbasvir","type":"EXPERIMENTAL"},{"label":"Deferred Treatment Group (DTG): Placebo > Grazoprevir/Elbasvir","type":"PLACEBO_COMPARATOR"}],"summary":"This is a randomized, parallel-group, placebo-controlled, multi-site, multinational, double-blind followed by open label period, Phase 3 trial of 100 mg of grazoprevir (MK-5172) in combination with 50 mg of elbasvir (MK-8742) (grazoprevir/elbasvir fixed-dose combination \\[FDC\\]) in treatment-naïve (TN) participants with chronic hepatitis C virus (HCV), genotype (GT) 1, 4 or 6 infection. The primary hypothesis is that the percentage of participants receiving grazoprevir/elbasvir FDC in the Immediate Treatment Group (ITG) achieving Sustained Virologic Response 12 weeks after the end of all study therapy (SVR12) will be superior to the historical reference rate of 73%.","primaryOutcome":{"measure":"Percentage of Participants Achieving Sustained Virologic Response 12 Weeks After the End of All Study Therapy (SVR12)","timeFrame":"12 weeks after end of all therapy (Study Week 24)","effectByArm":[{"arm":"Immediate Treatment Group (ITG): Grazoprevir/Elbasvir","deltaMin":94.2,"sd":null}],"pValues":[{"comp":"OG000","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":6},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["30311701","29761174","35920743","33319038","29461687"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":365},"commonTop":["Upper respiratory tract infection","Headache","Diarrhoea","Fatigue","Alanine aminotransferase increased"]}}